文献速递外周动脉疾病

膝下慢性肢体威胁性缺血血运重建结局的系统综述与荟萃分析

A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2019-05-28

该系统综述与荟萃分析纳入44项前瞻性研究、8602例膝下慢性肢体威胁性缺血(CLTI)患者,评估不同血运重建方式的患者相关结局。围手术期结局各方式相似;大隐静脉旁路移植通畅率最高,人工血管旁路移植至膝下目标时截肢和通畅结局明显较差;药物洗脱支架在膝下动脉通畅率优于裸金属支架。总体证据质量低,研究偏倚风险中至高。

要点

  • 围手术期(30天)死亡率、截肢率和主要不良心脏事件在各血运重建方式间大致相似。
  • 大隐静脉旁路移植1年和2年通畅率最高(一期87%、78%;二期94%、87%)。
  • 人工血管旁路移植至膝下目标时截肢和通畅结局明显劣于静脉旁路移植。

核心结论

  • 当前指导CLTI治疗决策的证据存在重大局限性,尤其是经腔内方式治疗严重解剖病变模式时。
  • 围手术期(30天)死亡率、截肢率和主要不良心脏事件在各方式间大致相似。
  • 大隐静脉旁路移植通畅率最高,而人工血管旁路移植至膝下目标时通畅率和保肢率均明显较差。

研究设计与样本

  • 系统综述与荟萃分析,检索多个数据库至2017年5月7日。
  • 纳入44项前瞻性研究,共8602例成人CLTI患者,随访至少1年。
  • 由独立配对评审员筛选文章并提取数据,采用随机效应荟萃分析合并结局。

主要发现

  • 膝下病变患者大隐静脉移植1年和2年通畅率:一期87%、78%,二期94%、87%,高于所有其他干预。
  • 药物洗脱支架在膝下动脉1年一期通畅率73%,优于裸金属支架的50%,与球囊血管成形术的66%至少相当。
  • 2年生存率、大截肢率和无截肢生存率在腔内干预与静脉旁路移植间大致相似,人工血管旁路移植肢体丧失率更高。
  • 人工血管旁路移植在截肢和通畅结局方面明显劣于静脉旁路移植,尤其是膝下目标2年及以后。

关键数值与推荐

  • 膝下病变大隐静脉移植1年一期通畅率87%、二期94%;2年一期78%、二期87%。
  • 膝下动脉药物洗脱支架1年一期通畅率73%,裸金属支架50%,球囊血管成形术66%。

临床怎么用

  • CLTI血运重建决策时应优先考虑大隐静脉旁路移植以获得最佳通畅率。
  • 避免将人工血管旁路移植用于膝下目标,因其截肢和通畅结局明显较差。
  • 膝下局灶病变可考虑药物洗脱支架或球囊血管成形术,两者通畅率相当。
  • 需结合肢体严重程度和解剖分期进行个体化决策,因当前证据质量低。

局限性

  • 纳入研究总体偏倚风险中至高,证据质量低。
  • 患者风险、肢体威胁严重程度和解剖特征存在异质性,使直接比较困难。
  • 无研究纳入长段胫动脉病变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal strategy for revascularization in infrainguinal chronic limb-threatening ischemia (CLTI) remains debatable. Comparative trials are scarce, and daily decisions are often made using anecdotal or low-quality evidence. METHODS: We searched multiple databases through May 7, 2017, for prospective studies with at least 1-year follow-up that evaluated patient-relevant outcomes of infrainguinal revascularization procedures in adults with CLTI. Independent pairs of reviewers selected articles and extracted data. Random-effects meta-analysis was used to pool outcomes across studies. RESULTS: We included 44 studies that enrolled 8602 patients. Periprocedural outcomes (mortality, amputation, major adverse cardiac events) were similar across treatment modalities. Overall, patients with infrapopliteal disease had higher patency rates of great saphenous vein graft at 1 and 2 years (primary: 87%, 78%; secondary: 94%, 87%, respectively) compared with all other interventions. Prosthetic bypass outcomes were notably inferior to vein bypass in terms of amputation and patency outcomes, especially for below knee targets at 2 years and beyond. Drug-eluting stents demonstrated improved patency over bare-metal stents in infrapopliteal arteries (primary patency: 73% vs 50% at 1 year), and was at least comparable to balloon angioplasty (66% primary patency). Survival, major amputation, and amputation-free survival at 2 years were broadly similar between endovascular interventions and vein bypass, with prosthetic bypass having higher rates of limb loss. Overall, the included studies were at moderate to high risk of bias and the quality of evidence was low. CONCLUSIONS: There are major limitations in the current state of evidence guiding treatment decisions in CLTI, particularly for severe anatomic patterns of disease treated via endovascular means. Periprocedural (30-day) mortality, amputation, and major adverse cardiac events are broadly similar across modalities. Patency rates are highest for saphenous vein bypass, whereas both patency and limb salvage are markedly inferior for prosthetic grafting to below the knee targets. Among endovascular interventions, percutaneous transluminal angioplasty and drug-eluting stents appear comparable for focal infrapopliteal disease, although no studies included long segment tibial lesions. Heterogeneity in patient risk, severity of limb threat, and anatomy treated renders direct comparison of outcomes from the current literature challenging. Future studies should incorporate both limb severity and anatomic staging to best guide clinical decision making in CLTI.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Almasri J, Adusumalli J, Asi N, et al. A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. J Vasc Surg. 2019. PMID: 31159976. doi:10.1016/j.jvs.2018.01.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。